[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP1455816A4 - Peptides de liaison hla de classe i et ii et leurs utilisations - Google Patents

Peptides de liaison hla de classe i et ii et leurs utilisations

Info

Publication number
EP1455816A4
EP1455816A4 EP01274676A EP01274676A EP1455816A4 EP 1455816 A4 EP1455816 A4 EP 1455816A4 EP 01274676 A EP01274676 A EP 01274676A EP 01274676 A EP01274676 A EP 01274676A EP 1455816 A4 EP1455816 A4 EP 1455816A4
Authority
EP
European Patent Office
Prior art keywords
hla class
binding peptides
peptides
immunogenic
allele
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01274676A
Other languages
German (de)
English (en)
Other versions
EP1455816A2 (fr
Inventor
Alessandro Sette
John Sidney
Scott Southwood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmexa Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Priority to EP07023116A priority Critical patent/EP1911461B1/fr
Publication of EP1455816A2 publication Critical patent/EP1455816A2/fr
Publication of EP1455816A4 publication Critical patent/EP1455816A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP01274676A 2000-10-19 2001-10-18 Peptides de liaison hla de classe i et ii et leurs utilisations Withdrawn EP1455816A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP07023116A EP1911461B1 (fr) 2000-10-19 2001-10-18 Peptides de liaisons HLA de classe I et II et leurs utilisations

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24235000P 2000-10-19 2000-10-19
US242350P 2000-10-19
US28562401P 2001-04-20 2001-04-20
US285624P 2001-04-20
PCT/US2001/051650 WO2003040165A2 (fr) 2000-10-19 2001-10-18 Peptides de liaison hla de classe i et ii et leurs utilisations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP07023116A Division EP1911461B1 (fr) 2000-10-19 2001-10-18 Peptides de liaisons HLA de classe I et II et leurs utilisations

Publications (2)

Publication Number Publication Date
EP1455816A2 EP1455816A2 (fr) 2004-09-15
EP1455816A4 true EP1455816A4 (fr) 2007-03-28

Family

ID=26935024

Family Applications (2)

Application Number Title Priority Date Filing Date
EP01274676A Withdrawn EP1455816A4 (fr) 2000-10-19 2001-10-18 Peptides de liaison hla de classe i et ii et leurs utilisations
EP07023116A Expired - Lifetime EP1911461B1 (fr) 2000-10-19 2001-10-18 Peptides de liaisons HLA de classe I et II et leurs utilisations

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP07023116A Expired - Lifetime EP1911461B1 (fr) 2000-10-19 2001-10-18 Peptides de liaisons HLA de classe I et II et leurs utilisations

Country Status (5)

Country Link
EP (2) EP1455816A4 (fr)
AT (1) ATE536187T1 (fr)
AU (1) AU2001298049A1 (fr)
CA (1) CA2425648A1 (fr)
WO (1) WO2003040165A2 (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002227406A1 (en) * 2000-12-13 2002-06-24 Argonex Pharmaceuticals Mhc class i associated peptides for prevention and treatment of tuberculosis
WO2003008537A2 (fr) * 2001-04-06 2003-01-30 Mannkind Corporation Sequences d'epitope
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
US7049413B2 (en) * 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
WO2002094994A2 (fr) 2001-05-18 2002-11-28 Mayo Foundation For Medical Education And Research Polypeptides chimeres specifiques d'antigene activant des lymphocytes t
ES2606537T3 (es) 2001-10-23 2017-03-24 Psma Development Company L.L.C. Anticuerpos contra PSMA
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
EP1670509A4 (fr) * 2003-09-03 2007-10-31 Dendritherapeutics Inc Vaccins multiplex
IL157772A (en) * 2003-09-04 2016-06-30 Bmr Solutions Ltd Compounds containing oligopeptide derived from turtle larvae and their use to encourage mammalian hemophysis
WO2005037855A2 (fr) * 2003-10-17 2005-04-28 Pecos Labs, Inc. Epitopes de lymphocytes t convenant pour un vaccin contre la peste et comme outils de diagnostic, et procede d'identification correspondant
CA2552508A1 (fr) * 2003-12-31 2005-09-29 Pharmexa Inc. Induction de reponses immunitaires cellulaires au papillomavirus humain utilisant des compositions peptidiques et d'acides nucleiques
GB0406054D0 (en) * 2004-03-17 2004-04-21 Univ Nottingham Trent Prostatic acid phosphatase antigens
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
WO2005105993A1 (fr) * 2004-04-30 2005-11-10 Nec Corporation Peptide de liaison hla, précurseur, fragment d’adn de codage identique et vecteur recombinant
JP4731867B2 (ja) 2004-10-01 2011-07-27 国立大学法人三重大学 Ｃｄ８陽性の細胞傷害性ｔリンパ球の誘導方法
DE102004049223A1 (de) 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
EP1709971A1 (fr) * 2005-04-06 2006-10-11 Ganymed Pharmaceuticals AG Antigènes peptidiques utiles pour la prophylaxie, le traitement et le diagnostic des infections de poxvirus
CA2612494A1 (fr) * 2005-06-17 2006-12-28 Mannkind Corporation Analogues d'epitopes
BRPI0504117A (pt) 2005-09-05 2007-05-22 Fundacao De Amparo A Pesquisa epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção
ATE461216T1 (de) * 2006-01-25 2010-04-15 Viro Pharmaceuticals Gmbh & Co Humaner verstärker der viralen infektion (sevi) und seine anwendung
WO2007097561A1 (fr) 2006-02-20 2007-08-30 Ewha University - Industry Collaboration Foundation Peptide présentant une activité de pénétration de membrane cellulaire
EP1840133A1 (fr) * 2006-03-29 2007-10-03 Global Biotech Development Corp. Ltd. Nouveaux peptides immunomodulants
US20080107668A1 (en) * 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP2091965B9 (fr) * 2006-10-17 2013-09-25 Oncotherapy Science, Inc. Vaccins peptidiques pour des cancers exprimant les polypeptides mphosph1 ou depdc1
US20090117140A1 (en) * 2007-09-26 2009-05-07 Mayumi Nakagawa Human papilloma virus dominant CD4 T cell epitopes and uses thereof
WO2009067584A1 (fr) * 2007-11-20 2009-05-28 Duke University Procédés et compositions permettant de moduler l'architecture, la pharmacocinétique et la biodistribution d'un médicament-polymère
EP2227486B1 (fr) * 2007-11-20 2017-03-08 Vianex S.A. Analogues peptidiques et leurs conjugués
AU2008338063B2 (en) * 2007-12-19 2013-03-14 Rhovac Aps RhoC-based immunotherapy
US20100166782A1 (en) * 2008-07-25 2010-07-01 Martha Karen Newell Clip inhibitors and methods of modulating immune function
US8975086B2 (en) 2008-08-28 2015-03-10 Oncotherapy Science, Inc. Method for treating or preventing bladder cancer using the DEPDC1 polypeptide
EP2334318B1 (fr) 2008-10-06 2016-02-10 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Peptides stimulateurs derives de l'integrase de vih-1 interferant avec la liaison entre l'integrase et la proteine rev
EP2391635B1 (fr) 2009-01-28 2017-04-26 Epimmune Inc. Polypeptides de liaison de pan-dr et leurs utilisations
JP5317336B2 (ja) * 2009-02-23 2013-10-16 国立大学法人東北大学 質量分析装置を用いたタンパク質定量のための評価用ペプチド、人工標準タンパク質、及びタンパク質の定量方法
BRPI0924827A2 (pt) * 2009-04-02 2019-01-08 Vaxon Biotech identificação, otimização e uso de epítopos hla-a24 crípticos para imunoterapia
US8431530B2 (en) * 2009-06-12 2013-04-30 Morehouse School Of Medicine Compositions and methods for treating aids or cancer by inhibiting the secretion of microparticles
US9023802B2 (en) * 2009-12-14 2015-05-05 Immatics Biotechnologies Gmbh HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
JP5564730B2 (ja) 2011-08-12 2014-08-06 オンコセラピー・サイエンス株式会社 Ｍｐｈｏｓｐｈ１ペプチドおよびそれを含むワクチン
GB201300683D0 (en) * 2013-01-15 2013-02-27 Apitope Int Nv Peptide
US10364451B2 (en) 2013-05-30 2019-07-30 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10392611B2 (en) 2013-05-30 2019-08-27 Duke University Polymer conjugates having reduced antigenicity and methods of using the same
US10272144B2 (en) 2013-07-31 2019-04-30 Bioventures, Llc Compositions for and methods of treating and preventing targeting tumor associated carbohydrate antigens
DK3140317T3 (da) 2014-05-09 2020-07-20 Univ Southampton Peptid-induceret nk-celleaktivering
WO2016154530A1 (fr) 2015-03-26 2016-09-29 Duke University Agents thérapeutiques ciblés comprenant des fusions protéine-biopolymère multivalentes
IL254129B2 (en) 2015-03-27 2023-10-01 Immatics Biotechnologies Gmbh New peptides and a combination of peptides for use in immunotherapy against various tumors
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
US11155585B2 (en) * 2015-07-09 2021-10-26 Intervacc Ab Vaccine against S. suis infection
US11458205B2 (en) 2015-08-04 2022-10-04 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
WO2017026503A1 (fr) 2015-08-12 2017-02-16 オンコセラピー・サイエンス株式会社 Peptide dérivé du depdc1 et vaccin le contenant
CN108699111B (zh) 2015-10-08 2022-11-01 肿瘤疗法科学股份有限公司 Mphosph1衍生的肽和包含它们的疫苗
GB201520570D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
WO2017210476A1 (fr) 2016-06-01 2017-12-07 Duke University Biocapteurs ne s'encrassant pas
WO2018053201A1 (fr) 2016-09-14 2018-03-22 Duke University Nanoparticules à base de polypeptide tribloc pour l'administration de médicaments hydrophiles
KR20190064600A (ko) 2016-09-23 2019-06-10 듀크 유니버시티 Lcst 거동을 갖는 비구조화된 비-반복적 폴리펩티드
CA3042703A1 (fr) * 2016-11-07 2018-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Developpement d'epitopes agonistes du papillomavirus humain
WO2018132732A1 (fr) 2017-01-12 2018-07-19 Duke University Biomatériaux hybrides lipide-polypeptide génétiquement codés qui offrent un auto-assemblage hiérarchique déclenché par la température
WO2018187356A2 (fr) * 2017-04-03 2018-10-11 Neon Therapeutics, Inc. Antigènes protéiques et leurs utilisations
US11554097B2 (en) 2017-05-15 2023-01-17 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
US11680083B2 (en) 2017-06-30 2023-06-20 Duke University Order and disorder as a design principle for stimuli-responsive biopolymer networks
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
WO2020028806A1 (fr) 2018-08-02 2020-02-06 Duke University Protéines de fusion à double agoniste
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
AU2020315981A1 (en) * 2019-07-24 2022-02-17 Agenus Inc. Antigenic polypeptides and methods of use thereof
NL2030990B1 (en) * 2022-02-17 2023-09-01 Academisch Ziekenhuis Leiden T cell receptors directed against jchain and uses thereof
CN117285597B (zh) * 2023-11-27 2024-01-26 中国科学院烟台海岸带研究所 一种具有降尿酸功能的五肽kk5及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027954A2 (fr) * 1997-12-03 1999-06-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE342730T1 (de) 1992-08-07 2006-11-15 Pharmexa Inc Hla bindepeptide und ihre verwendungen
BR9406652A (pt) 1993-03-05 1996-09-10 Cytel Corp Composição
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
AU698962B2 (en) 1993-09-14 1998-11-12 Epimmune, Inc. Alteration of immune response using pan DR-binding peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US6019974A (en) 1996-01-26 2000-02-01 Emory University SPE-4 peptides
CA2262006A1 (fr) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Procedes et reactifs destines a l'immunisation genetique
US6128946A (en) 1997-06-26 2000-10-10 Crane Nuclear, Inc. Method and apparatus for on-line detection of leaky emergency shut down or other valves
AU6226100A (en) 1999-07-19 2001-04-24 Epimmune, Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
US7026443B1 (en) 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999027954A2 (fr) * 1997-12-03 1999-06-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Micelles mixtes de lipopeptides pour l'induction d'une reponse immunitaire

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HADIDA F ET AL: "CARBOXYL-TERMINAL AND CENTRAL REGIONS OF HUMAN IMMUNODEFICIENCY VIRUS-1 NEF RECOGNIZED BY CYTOTOXIC T LYMPHOCYTES FROM LYMPHOID ORGANS AN IN-VITRO LIMITING DILUTION ANALYSIS", JOURNAL OF CLINICAL INVESTIGATION, vol. 89, no. 1, 1992, pages 53 - 60, XP002406423, ISSN: 0021-9738 *

Also Published As

Publication number Publication date
WO2003040165A3 (fr) 2004-06-24
CA2425648A1 (fr) 2002-04-19
AU2001298049A8 (en) 2005-11-03
ATE536187T1 (de) 2011-12-15
EP1911461B1 (fr) 2011-12-07
WO2003040165A2 (fr) 2003-05-15
EP1455816A2 (fr) 2004-09-15
EP1911461A2 (fr) 2008-04-16
EP1911461A3 (fr) 2008-07-16
AU2001298049A1 (en) 2003-05-19

Similar Documents

Publication Publication Date Title
AU2001298049A8 (en) Hla class i and ii binding peptides and their uses
EP1189624A4 (fr) Peptides de liaison a hla et leurs utilisations
BR9406652A (pt) Composição
EP0907370A4 (fr) Peptides de fixation de hla-a2.1 et leurs utilisations
IL106610A0 (en) Hla binding peptides and their uses
DK0941478T4 (da) Assaymetode for peptidspecifikke T-celler
TR200101256T2 (tr) DNA ile aşılamada geliştirmeler
BR0017136A (pt) Peptìdeos de ligação ao hla e seus usos.
AU2273701A (en) Hla class i a2 tumor associated antigen peptides and vaccine compositions
EP1089757A4 (fr) Peptides liant hla-a2 et leurs utilisations
DE60331224D1 (de) Subtilisin-carlsberg-proteine mit verminderter immunogenität
EP1320377A4 (fr) Peptides de liaison aux hla et leurs utilisations
WO2002094313A3 (fr) Composition de vaccin
PT1230261E (pt) Derivados nonapeptídicos de ny-eso-1 e suas utilizações
WO1999047102A3 (fr) Methodes pour une presentation amelioree de l'antigene sur des cellules presentatrices de l'antigene, et compositions produites selon ces methodes
EP1605039A4 (fr) Cellule dendritique presentant des derives de alpha-glycosylceramide et un antigene et utilisable dans la suppression de la reponse immunitaire
WO2004020592A3 (fr) Vaccination genetique retrocanalaire par l'intermediaire des glandes salivaires

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030519

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20070226

17Q First examination report despatched

Effective date: 20070529

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PHARMEXA INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071211